Kornimate/medical-research-clean huggingface dataset:
investigation of the effects of dual task training on dual task performance in individuals with scoliosis

Conditions: Idiopathic Scoliosis

Summary: in this study, "single task" and "dual task" groups will be formed in individuals aged 10-18 years with scoliosis. for 12 weeks, scoliosis-specific three-dimensional exercises will be applied to both groups. the single task group will receive only motor exercise training, while the dual task group will receive both motor and cognitive exercise training. at the end of the study, the dual-task performance of both groups will be evaluated and the effects of dual task training on individuals with scoliosis will be analyzed.

scoliosis is a term used to describe changes in the shape and position of the spine and chest cage. essentially, scoliosis involves lateral deviation and rotations of the vertebrae, accompanied by changes in the sagittal plane, creating a three-dimensional deformity. the progressive nature of scoliotic deformity underscores the importance of controlling these components through conservative methods. without control, scoliosis can lead to postural, balance, and locomotor disorders due to compromised sensory integrity and inadequate proprioceptive feedback. despite compromised postural control and continuity in individuals with adolescent idiopathic scoliosis (ais), maintaining daily life activities and body orientation is crucial for controlling the progression of scoliosis. the daily routine of individuals with ais often involves simultaneous engagement in postural control alongside other daily activities. these routines and exercises frequently incorporate dual-task components. our study aims to examine the effectiveness of single-task and dual-task walking and balance exercises in individuals with scoliosis, as well as their contributions to scoliosis-specific assessments

Eligibility criteria:
inclusion criteria: 1. individuals between the ages of 10-16 2. individuals with idiopathic scoliosis 3. individuals with curve degrees between 10 and 40 4. individuals with a body mass index of less than 30 kg\\m2. 5. be willing to participate in the tests and have the cognitive ability to complete the tests. exclusion criteria: 1. having other types of scoliosis other than idiopathic scoliosis 2. individuals with previous scoliosis or any spine-related conservative treatment or surgery 3. acute (fracture, surgery); cardiovascular system (heart failure, arrhythmia...); nervous system diseases (epilepsy, vertigo...); sensory organs (vision or hearing loss...); musculoskeletal disorders (rheumatism, hypermobility syndrome...) 4. taking any regular medication that may affect balance (ssri, psycholeptic, anti-epileptic medication...) 5. playing sports at a professional level 6. using a brace, starting to use a brace

Keywords: adolescent dual task scoliosis gait parameters
identification and characterization of molecular markers in musculoskeletal tumors

Conditions: Soft Tissue and Bone Tumors; Sarcoma; Sarcoma of Bone; Soft Tissue Sarcoma

Summary: the aim of the study is to improve the understanding of molecular mechanisms in the development and progression of musculoskeletal tumors. these tumors do have in general unfavorable prognosis and conventional treatments (e.g. surgery, radiotherapy or chemotherapy) could not enhance the prognosis of these patients during the last ten to fifteen years. therefore the investigators chose a new way, as they try to identify markers on a genetic level, who ideally act as a basis to develop new treatment options.

to definitely asses such molecular markers in musculoskeletal tumors they have to be identified in human patient samples with corresponding tumors, before molecular markers can be validated in animal models. just because these soft tissue and bone tumors are rare (compared to breast and lung carcinomas), it is of great importance that samples from all patients treated at balgrist university hospital are collected systematically und stored correspondingly. only like this valid statements can be done. therefore the investigators intent to collect tissue and blood samples from all patients who agree in participating in the study. the samples will be taken during routine biopsies and operations. to compare tumor tissue and healthy tissue it is also planed to take samples from tumor free patients who undergo a knee replacement surgery. the investigators would store the surgical waste and involve these samples in the analyzes. clinical data regarding diagnosis and examination findings, as well as tissue from biopsies and surgeries will be collected prospectively. the tissue will be frozen in liquid nitrogen according to standard procedures and stored until the molecular analyzes at the laboratory of orthopedic research at balgrist university hospital. the processing involves expression analyzes such as polymerase chain reaction, western blot, micro arrays, immunohistochemistry and tissue array. the dna from the taken blood samples shall be compared with the dna found in the tumor.

Eligibility criteria:
inclusion criteria: * surgery or biopsy of a bone- or soft tissue tumor * informed consent exclusion criteria: * patients wish
a study to evaluate the safety and efficacy of ruxolitinib cream in participants with prurigo nodularis (pn)

Conditions: Prurigo

Summary: the purpose of this study is to evaluate the safety and tolerability of ruxolitinib cream in participants with prurigo nodularis (pn).

the study comprises of a 12 week double-blind, vehicle-controlled (dbvc) treatment period, followed by a 40 week open label extension period, and 30 day safety follow-up period during the double blind period, all pn-affected areas identified at baseline will be treated, and during the open label period, only active pn-affected areas will be treated.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of pn ≥ 3 months before screening. * ≥ 6 pruriginous lesions on ≥ 2 different body areas (such as right and left leg) at screening and baseline having a treatment area \<20% bsa. * iga-cpg-s score of ≥ 2 at screening and baseline. * baseline pn-related wi-nrs score ≥ 7. * willingness to avoid pregnancy or fathering children. exclusion criteria: * chronic pruritus due to a condition other than pn * total estimated bsa treatment area (excluding the scalp) \> 20%. * neuropathic and psychogenic pruritus * active atopic dermatitis lesions within 3 months of screening and baseline. * uncontrolled thyroid function * concurrent skin or other serious or unstable medical conditions which may interfere with the evaluation of pn such as immunocompromised status, acute/chronic infections, active malignancy, history of tb, history of dvt/vte, etc protocol defined abnormal laboratory results. * use of any protocol-defined prohibited medication unless a washout is completed or use of medication known to cause itching. * psoralen and ultraviolet a or ultraviolet b therapy within 4 weeks before baseline or ultraviolet light therapy or prolonged exposure to natural or artificial sources of ultraviolet radiation (within 2 weeks before baseline * pregnant or lactating, or considering pregnancy. * history of alcoholism or drug addiction within 1 year * known allergy or reaction to any of the components of the study drug. * committed to a mental health institution by virtue of an order issued either by the judicial or the administrative authorities. * employees of the sponsor or investigator or otherwise dependents of them. * the following participants are excluded in france: 1. vulnerable populations according to article l.1121-6 of the french public health code. 2. adults under legal protection or who are unable to express their consent per article l.1121-8 of the french public health code. 3. individuals not affiliated with the social security system.

Keywords: prurigo prurigo nodularis pn skin diseases dermatitis eczematous ruxolitinib incb 18424
bio.master.biomonitor 2 study

Conditions: Tachyarrhythmia; Atrial Fibrillation; Syncope

Summary: the objective of the study is to confirm safety and efficacy of the biomonitor 2. the data is collected to support the regulatory approval of this product in countries outside the ce region.


Eligibility criteria:
inclusion criteria: * patients without history of atrial fibrillation and with an indication for biomonitor 2 device or paients planned for loop recorded guided af-therapy management, with either current known and documented paroxysmal atrial fibrillation or with current known and documented persistent atrial fibrillation indicated for an ablation or was ablated within the last four weeks. * patient is able to understand the nature of the study and provides written informed consent. * patient is able and willing to complete the planned follow-up visits at the investigational site. * patient accepts the home monitoring® concept. * age is ≥ 18 years. exclusion criteria: * patients implanted with icd or pacemaker. * patient who is pregnant and/or breast-feeding or who intends to become pregnant during the time of the study will be excluded. * life expectancy of less than 6 months. * participation in another interventional clinical investigation. participation in a non-interventional study is permitted.
microneedle pretreatment as a strategy to improve the effectiveness of topical anesthetics formulations

Conditions: Oral Cavity Disease

Summary: a randomized, crossover, double-blind, two-sessions clinical trial with 30 male volunteers was performed to access pain of local anesthesia after using a topical anesthetic associated or not with prior application of microneedles to the palatal mucosa region

a randomized, crossover, double-blind, two-sessions clinical trial with 30 male volunteers was performed by applying a microneedle patch and as a negative control the an identical patch but without microneedles sticking out and after the topical anesthetic was applied for in one session 2 minutes and the other session 5 minutes and the investigators evaluated the pain of needle introduction and the injection of the anesthetic. the application force of the microneedles was standardized to 10n by an applicator composed of a 5 ml syringe and a spring. pain and discomfort associated to the procedure was evaluated with a visual analogue scale (vas), in these two different moments, introduction of the needle and injection of the anesthetic.

Eligibility criteria:
inclusion criteria: - healthy male exclusion criteria: * volunteers were free from cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal and haematological diseases, psychiatric disorders, smokers or alcoholic.

Keywords: microneedles oral cavity transbuccal administration
clinical validation of an optimized multi-target stool dna (mt-sdna 2.0) test, for colorectal cancer screening "blue-c"

Conditions: Colorectal Cancer

Summary: the primary objective of this study is to assess the sensitivity for colorectal cancer (crc) and specificity of the mt-sdna 2.0 test.

subjects 40 years of age and older scheduled for a screening colonoscopy will be enrolled. subject will complete the mt-sdna 2.0 test and the commercially available fit, followed by completion of a screening colonoscopy. the results of the mt-sdna screening test and fit will not be provided to investigators for clinical management of the study subject. personnel performing the colonoscopy and producing the resulting report and personnel performing histopathologial review of reports or tissue (if applicable) will remain blinded to the results of the mt-sdna 2.0 screening test results.

Eligibility criteria:
inclusion criteria: subjects must meet the following criteria to be eligible for the study: 1. subject is ≥ 40 years of age at the time of enrollment. 2. subject presents for a screening colonoscopy per standard of care. 3. subject has no symptoms or signs that require immediate, or near term, referral for diagnostic or therapeutic colonoscopy. 4. subject is able and willing to sign informed consent exclusion criteria: 1. subject has a history of crc or advanced precancerous lesions. 2. subject has a diagnosis or medical / family history of any of the following conditions, including: * familial adenomatous polyposis (also referred to as "fap", including attenuated fap and gardner's syndrome), * hereditary non-polyposis crc syndrome (also referred to as "hnpcc" or "lynch syndrome"), * other hereditary cancer syndromes including but are not limited to peutz-jeghers syndrome, myh-associated polyposis (map), turcot's (or crail's) syndrome, cowden's syndrome, juvenile polyposis, neurofibromatosis, or familial hyperplastic polyposis. 3. subject has a diagnosis or personal history of inflammatory bowel disease (ibd) including chronic ulcerative colitis and/or crohn's disease. 4. subject has a diagnosis of cronkhite-canada syndrome. 5. subject has had a positive cologuard within the previous 2 years, or fecal occult blood test or fit within the previous 6 months. 6. subject has undergone a colonoscopy within the previous 9 years with the exception of a failed colonoscopy due to poor bowel preparation. failed colonoscopy must have been within the past year and without therapeutic intervention. 7. subject has had overt rectal bleeding within the previous 30 days. 8. subject has any condition that in the opinion of the investigator should preclude participation in the study.

Keywords: sample collection stool dna colonoscopy
evaluation of 3d printed myoelectric prosthetic devices in children with upper congenital limb deficiency

Conditions: Limb Deformities, Congenital; Upper Extremity Deformities, Congenital; Congenital Abnormalities

Summary: this will be a prospective study over a 14-month duration with clinical evaluations throughout. limitless solutions will provide prosthetics and training system for study subjects that qualify for enrollment.

prosthetics for children are costly and those families who do get them often find that children don't use them for very long for a variety of reasons, including weight and ease of use. limitless solutions has developed technology to create personalized bionics for people with disabilities at an affordable cost. this will be a prospective study over a 14-month duration with clinical evaluations throughout. limitless solutions will provide prosthetics and training system for study subjects free of charge. during each visit, the study team will include an occupational therapist, a prosthetist, a study coordinator, and a research volunteer along with limitless support staff and a supervising physician. subject will complete quality of life questionnaires throughout their participation.

Eligibility criteria:
inclusion criteria: * children between the ages of 7 to 17 * congenital/infant upper limb deficiency specifically transhumeral and transradial limb deficiency as identified by limbitless solutions. exclusion criteria: * non-english-speaking children and families. * any shoulder or wrist disarticulation will be excluded.
shortened high-dose palliative radiotherapy for lung cancer

Conditions: Stage IV Lung Cancer

Summary: the ship-rt study aims to investigate the safety and efficacy of reducing the number of rt fractions and rt duration, compared to the current standard of care (36gy in 12 fractions over 16 days), by using shortened hypofractionated accelerated palliative radiotherapy (30gy in 6 alternate-day fractions), aided by contemporary rt planning, verification, and delivery techniques.


Eligibility criteria:
inclusion criteria: * age ≥ 18 * patient has locally advanced (stage iiib or iiic) or metastatic (stage iv) nsclc * patient is treatment naïve or had limited progression after first-line systemic therapy (using chemotherapy, immunotherapy, or targeted therapy) * patient is suitable for high dose palliative rt (36gy in 12# or 39gy in 13#) * obtained written informed consent for the ship-rt study. * patients receiving rt after first-line systemic therapy must have a wash-out period of at least 3 weeks (i.e., 3-4 weeks). * treatment naïve patients should be able to proceed to definitive systemic therapy without undue delay, i.e., within 3-4 weeks. exclusion criteria: * contraindication for thoracic rt * requiring lung rt after second-line systemic therapy for nsclc * has more than 1 cancer that is requiring active treatment * on cytotoxic treatment for rheumatoid arthritis or connective tissue disorders * poor life expectancy, likely less than 6 months * patients with difficulty regarding compliance to the study treatment or follow-up * previous radiotherapy to the same area

Keywords: radiotherapy lung cancer
the effects of enzymes and flavonoids on inflammation and coagulation after marathon

Conditions: Inflammation; Death, Sudden, Cardiac; Death; Heart Diseases; Cardiovascular Diseases; Pathologic Processes; Death, Sudden; Blood Coagulation Disorders; Respiratory Tract Infections

Summary: the aim of the present study is to investigate changes in inflammatory status and incidence of infection after extreme aerobic physical stress (participation in a marathon). in addition, the impact of marathon running on the hemostasis and muscular state will be evaluated. changes at the inflammatory, muscular, and rheological level will be related to ingestion of oral hydrolytic enzymes and bioflavonoids.

the influence of extreme physical stress, such as that experienced during marathon competition, on the inflammatory system and coagulation has been investigated. however, up until now, countermeasures against these adverse effects are not adequately identified. immune-modulators (e.g. flavonoids) are known to be present in fruits and vegetables. there are also several different proteolytic and hydrolytic enzymes found in fruits most of whom are attributed protective properties. therefore, 160 trained and untrained runners will consume a mixture of different enzymes and flavonoids (wobenzym plus®) or pl 1 (placebo) and effects on changes in inflammation and hemostasiologic parameters will be investigated during and after extreme physical stress (participation in a marathon race). the clinical result of the perturbation of the immune system will be assessed by the wisconsin upper respiratory symptom survey (wurss-24) with regard to symptoms of the upper respiratory tract system. it is hypothesized that the intake of a product with immunomodulatory potential (wobenzym plus ®, consisting of hydrolytic enzymes and flavonoids) can positively influence both inflammation and blood coagulation pertubations observed after a marathon race.

Eligibility criteria:
inclusion criteria: * • healthy male * age 20-65 years * history of at least one successfully finished half marathon * intention to participate at the munich marathon 2013 * subject is able to read, understand, and sign a written informed consent to participate in the enzy-magic-study exclusion criteria: * known cardiac disease * known allergy against the active ingredient of the study medication or pineapple, papaya, or kiwi * known severe coagulopathy * known lactose intolerance * pharmaceutical treatment for diabetes mellitus or arterial hypertension * acute or chronic renal failure * acute or chronic liver disease * acute or chronic infection or inflammatory disease * use of medications or supplements influencing immune function * musculoskeletal or psychiatric disease * neoplasia * participation in other interventional trials

Keywords: exercise inflammation upper respiratory tract illness oral proteolytic and hydrolytic enzymes flavinoids
flat foot and coronal spinopelvic alignment

Conditions: Flat Foot [Pes Planus] (Acquired), Left Foot; Flat Foot [Pes Planus] (Acquired), Right Foot; Flat Foot Acquired Bilateral (Pes Planus); Pelvic Obliquity; Spinal Curvatures

Summary: this study aimed to present the influence of unilateral and bilateral flat foot on coronal spinopelvic alignment in asymptomatic young healthy males. it will be carried out by examining the medical reports of individuals who apply to the national health board to work in positions requiring physical fitness between january 2018 and january 2019. plain radiographies of the feet, pelvis, and spine will be analyzed. calcaneal pitch angle (cpa) for flat foot, pelvic obliquity (po), and cobb angle (ca) for spinal asymmetry will be measured. after all analyzes were completed, participants will be divided into 2 groups as unilateral (uniff) or bilateral (biff) flat foot, depending on the cpa measurements and will be compared.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) ranging between 18.5-24.9 kg/m2 (accepted as normal weight by world health organisation (who)) * age ranging between 18-25 years * male gender exclusion criteria: * being older than 25 years * bmi out of normal weight according to who * being female * history of spinal trauma/ surgery * having/had spinal disorders like spondylolisthesis, spondylodiscitis, etc. * having/had chronic inflammatory arthritis especially spodiloarthrosis (i.e., ankylosing spondylitis, psoriatic arthritis, etc.) * having/had a vertebral fracture * having/had aseptic necrosis of the vertebra * radiographs with inappropriate image qualities.

Keywords: flat foot pelvic obliquity spinal asymmetry cobb angle calcaneal pitch angle
covid-19 and chilblains

Conditions: Chilblains; COVID-19

Summary: chilblains (inflammatory lesion of the feet or hands) have been reported with an unusual frequency during the confinement period, most commonly in children, teenagers and young adults. the aim of the ecces study is to find out whether these manifestations of chilblains can be linked to the sars-cov-2 coronavirus. for this, an epidemiologic study will compare two types of family (or more precisely people who were confined together in march-april-may): * "case family" in which at least one of the members had chilblains * "comparator family" in which none of the members had chilblains environment (home lockdown) of the two types of family will be analyzed. each member of the "family" will be suggested doing a serological test.


Eligibility criteria:
inclusion criteria: * "case family" * at least one of the members with chilblains * diagnosis of chilblains (anamnesis and pictures) written informed consent * "comparator family" * none of the members with chilblains * one member matched on age (+/- 1 year) to a patient with chilblains * written informed consent exclusion criteria: - subject legally protected (under judicial protection, guardianship), persons deprived of liberty
acceptability/feasibility of hiv testing by elisa or rapid test to adult patients in paris, france

Conditions: HIV

Summary: cdc recommends universal hiv testing in all adults, at least once during life, to reduce the pool of infected patients unaware of their status. routine universal hiv testing can use "classical" elisa tests from serum, or rapid tests, ideally from finger-stick whole blood (fsb), which have shown close predictive values from classical tests. the investigators will compare the acceptability and feasibility of the two methods.

the multi-center prospective randomized study will compare the acceptability and feasibility of routine universal hiv testing to adult patients consulting their general practitioner in paris, france, using either the " classical " elisa tests from serum or rapid tests from fsb (insti®).

Eligibility criteria:
inclusion criteria: * adult patients consulting their general practitioner in paris, france exclusion criteria: * patients previously known as hiv-positive, * patients who declare having been tested hiv-negative less than three months ago, * patients who can not give informed consent

Keywords: adult outpatients paris, france